Results 101 to 110 of about 46,312 (227)

Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation -a look beyond the excellent results [PDF]

, 2012
In this overview we address the three phase III studies that compared new oral anticoagulants (dabigatran, rivaroxaban and apixaban) with warfarin in the setting of stroke prevention in atrial fibrillation.
Crippa, L, Falanga, A, Finazzi, G, Manotti, C., Marongiu, F, Moia, M, Palareti, G, Pengo, V, Poli, D, Policarpo, D, SIRAGUSA, Sergio, TESTA, Silvia, Tiraferri, E, Tosetto, A, Tripodi, A   +14 more
core   +1 more source

Factors affecting serum concentration of dabigatran in Asian patients with non-valvular atrial fibrillation

Journal of the Formosan Medical Association, 2019
Background/purpose: Dabigatran is effective in preventing ischemic stroke and systemic embolism in patients with atrial fibrillation. Although the therapeutic window for dabigatran is wide, its pharmacokinetic properties can differ between specific ...
Shin-Yi Lin, Sung-Chun Tang, Ching-Hua Kuo, Li-Kai Tsai, Shin-Joe Yeh, Li-Jiuan Shen, Jiann-Shing Jeng   +6 more
doaj   +1 more source

Safety and Efficacy of Minimally Interrupted Dabigatran vs Uninterrupted Warfarin Therapy in Adults Undergoing Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial.

JAMA Network Open, 2019
Importance Uninterrupted dabigatran therapy reduces stroke risk in patients with nonvalvular atrial fibrillation (NVAF) undergoing ablation and is associated with a lower bleeding risk than uninterrupted warfarin therapy.
A. Nogami, T. Harada, Y. Sekiguchi, R. Otani, Y. Yoshida, Kentaro Yoshida, Yukiko Nakano, N. Nuruki, Shiro Nakahara, M. Goya, H. Origasa, Y. Kihara, K. Hirao, K. Aonuma   +13 more
semanticscholar   +1 more source

UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays.

PLoS ONE, 2015
IntroductionThe fast, precise, and accurate measurement of the new generation of oral anticoagulants such as dabigatran and rivaroxaban in patients' plasma my provide important information in different clinical circumstances such as in the case of ...
Joachim Kuhn, Tatjana Gripp, Tobias Flieder, Marcus Dittrich, Doris Hendig, Jessica Busse, Cornelius Knabbe, Ingvild Birschmann   +7 more
doaj   +1 more source

Managing patients taking novel oral anticoagulants (NOAs) in dentistry: A discussion paper on clinical implications [PDF]

, 2016
Background The aim of this paper is to contribute to the discussion on how to approach patients taking new orally administered anticoagulants (NOAs) dabigatran etexilate (a direct thrombin inhibitor), rivaroxaban and apixaban (factor Xa inhibitors ...
Costantinides, Fulvia, Maglione, Michele, Pascazio, Lorenzo, Rizzo, Roberto   +3 more
core   +1 more source

Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding

Circulation, 2019
Background: Although dabigatran has a favorable risk-benefit profile compared with vitamin K antagonist therapy for venous thromboembolism and nonvalvular atrial fibrillation, major bleeding events, including gastrointestinal (GI) bleeding, may occur ...
Sake J. van der Wall, R. Lopes, J. Aisenberg, P. Reilly, J. van Ryn, S. Glund, Amelie Elsaesser, F. Klok, C. Pollack, M. Huisman   +9 more
semanticscholar   +1 more source

Re-evaluating Safety and Effectiveness of Dabigatran Versus Warfarin in a Nationwide Data Environment: A Prevalent New-User Design Study

Drugs - Real World Outcomes, 2019
Introduction The new user cohort design is widely used to assess the effects of a new drug, such as dabigatran, but inherently excludes some users due to prior use of the comparator drug, for example warfarin.
Hui-Min Diana Lin, Chao-Lun Lai, Yaa-Hui Dong, Yu-Kang Tu, K. Arnold Chan, Samy Suissa   +5 more
doaj   +1 more source

Dabigatran etexilate [PDF]

British Journal of Clinical Pharmacology, 2010
Eline A, Dubois, Adam F, Cohen
openaire   +2 more sources

Dental management of patients taking novel oral anticoagulants (NOAs): dabigatran [PDF]

, 2017
A new group of oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) with clear advantages over classic dicoumarin oral anticoagulants (warfarin and acenocoumarol) has been developed in recent years.
Albaladejo Martínez, Alberto, Alvarado Lorenzo, Alfonso, Curto Aguilera, Adrián   +2 more
core   +2 more sources

Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation [PDF]

, 2016
Background Transcatheter left atrial appendage occlusion (LAAO) is a promising therapy for stroke prophylaxis in non-valvular atrial fibrillation (NVAF) but its cost-effectiveness remains understudied. This study evaluated the cost- effectiveness of LAAO
Chow, Ines Hang-Iao, Kaya, Mehmet Gungor, Lam, Yat-Yin, Lee, Vivian Wing-Yan, Park, Jai-Wun, Tsai, Ronald Bing-Ching, Yan, Bryan Ping-Yen   +6 more
core   +1 more source